Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes.
Gilbert
Richard E
RE
Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. richard.gilbert@utoronto.ca
Kim
Sandra A
SA
Tuttle
Katherine R
KR
Bakris
George L
GL
Toto
Robert D
RD
McGill
Janet B
JB
Haney
Douglas J
DJ
Kelly
Darren J
DJ
Anderson
Pamela W
PW
D000328:Adult; D003404:Creatinine / Q000652:urine; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000652:urine*; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000652:urine*; D004311:Double-Blind Method; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008301:Maleimides / Q000627:therapeutic use*; D008875:Middle Aged; D010919:Placebos; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D064546:Protein Kinase C beta; D016212:Transforming Growth Factor beta / Q000235:genetics* / Q000652:urine
D004791:Enzyme Inhibitors; D007211:Indoles; D008301:Maleimides; D010919:Placebos; D016212:Transforming Growth Factor beta; C099154:ruboxistaurin; D003404:Creatinine; D011493:Protein Kinase C; D064546:Protein Kinase C beta